Arkolith/Insider Trading/CTMX/Form 4

Belvin Marcia

SVP, Chief Scientific OfficerCytomX Therapeutics, Inc. (CTMX) · full profile →Form 4 · filed Mar 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$202K
Net Open-Market Flow
-$202K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 17, 2026Sell(S)31K$6.42$202K301K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-26-000123) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML